Innovations for Changing the Face of Women’s Reproductive Health Therapeutics

At ObsEva, our passion and expertise in reproductive health and pregnancy therapeutics is helping millions of women worldwide lead healthier and more fulfilling lives.

Significant Unmet Needs in Reproductive Health

Millions of women worldwide suffer from reproductive health conditions that affect their quality of life or ability to conceive and may lead to complications during pregnancy.

Innovation From Conception to Birth and Beyond

ObsEva is advancing a robust pipeline of novel, orally-administered, clinical-stage compounds in the areas of uterine fibroids, endometriosis, assisted reproductive technology, and preterm labor.

Recent Updates

15 Jun 2018

ObsEva SA to Hold Investor Call to Announce Topline Results of the EDELWEISS Phase 2b Clinical Trial of Linzagolix (OBE2109) in Women with Endometriosis-Associated Pain on Monday June 18, 2018

Read more
01 Jun 2018

ObsEva SA to Seek SIX Share Listing

Read more
31 May 2018

ObsEva SA to Participate in Jefferies Global Healthcare Conference June 5-8, 2018

Read more
16 May 2018

ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update

Read more